Influence of baseline patient characteristics on response to once-monthly and daily oral ibandronate therapy: 2-year findings from mobile

被引：0

作者：

Reginster, J. Y.

Hawker, G.

Bolognese, M.

Coutant, K.

Hughes, C.

Sedarati, F.

Stone, M.

机构：

[1] Univ Liege, Liege, Belgium

[2] Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada

[3] Bethesda Hlth Res, Bethesda, MD USA

[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[5] Hoffmann La Roche Inc, Nutley, NJ 07110 USA

[6] Llandough Hosp, Cardiff, Wales

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：426 / 426

页数：1

共 39 条

[31] Monthly oral ibandronate is at least as effective as oral daily ibandronate in postmenopausal osteoporosis: 1-Year results from MOBILE.
Miller, PD
Drezner, HK
Delmas, PD
Stakkestad, JA
Hughes, C
Bonvoisin, B
Reginster, JY
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S94 - S94
[32] Monthly oral ibandronate is at least as effective as daily oral ibandronate in increasing hip BMD in postmenopausal osteoporosis: 1-year results from mobile
Cooper, C
Stepan, JJ
Lorenc, R
Hughes, C
Mairon, N
Sedarati, F
Reginster, JY
BONE, 2005, 36 : S417 - S417
[33] Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
Miller, PD
McClung, MR
Macovei, LV
Stakkestad, JA
Luckey, M
Bonvoisin, B
Reginster, JY
Recker, RR
Hughes, C
Lewiecki, EM
Felsenberg, D
Delmas, PD
Kendler, DL
Bolognese, MA
Mairon, N
Cooper, C
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (08) : 1315 - 1322
[34] Early Response to Once-monthly Oral Minodronate after Switching from Daily or Weekly Bisphosphonates in Japanese Osteoporotic Patients
Sakai, Akinori
Ikeda, Satoshi
Okimoto, Nobukazu
Teshima, Kitau
Arita, Shinobu
Matsumoto, Hidehiro
Tsurukami, Hiroshi
Okazaki, Yuichi
Nagashima, Masato
Fukuda, Fumio
Yoshioka, Toru
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
[35] Once monthly dosing increases the proportion of patients who respond to oral ibandronate: 1-year results from MOBILE.
Emkey, R
Felsenberg, D
Stepan, JJ
Hughes, C
Dumont, E
Van der Auwera, P
Recker, RR
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S447 - S447
[36] Oral Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis: Baseline Patient Demographics and Disease Characteristics from a 2-Year Phase III Trial (FREEDOMS II)
Calabresi, Peter A.
Goodin, Douglas
Jeffery, Douglas
Lublin, Fred D.
Rammohan, Kottil
Reder, Anthony T.
Vollmer, Timothy
Stites, Tracy
Li, Bingbing
Gottschalk, Rebecca
Malhotra, Manoj
NEUROLOGY, 2010, 74 (09) : A416 - A417
[37] Oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis: baseline patient demographics and disease characteristics front a 2-year phase III trial (FREEDOMS)
Kappos, Ludwig
Polman, Chris H.
Radue, Ernst-Wilhelm
O'Connor, Paul
Calabresi, Peter A.
Hohlfeld, Reinhard
Agoropolou, Catherine
Pohlmann, Harald
de Vera, Ana
MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S50 - S51
[38] Effectiveness and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy: 2-year findings from CHORDS
Weinstock-Guttman, B.
Bermel, R.
Csoboth, C.
Cutter, G.
Freedman, M.
Leist, T. P.
Ma, X.
Musch, B.
Reder, A.
Stankiewicz, J.
Wolinsky, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 43 - 43
[39] The Influence of Baseline Parameters on Changes in International Prostate Symptom Score with Dutasteride, Tamsulosin, and Combination Therapy among Men with Symptomatic Benign Prostatic Hyperplasia and an Enlarged Prostate: 2-Year Data from the CombAT Study
Roehrborn, Claus G.
Siami, Paul
Barkin, Jack
Damiao, Ronaldo
Becher, Edgardo
Minana, Bernardino
Mirone, Vicenzo
Castro, Ramiro
Wilson, Timothy
Montorsi, Francesco
EUROPEAN UROLOGY, 2009, 55 (02) : 461 - 471

← 1 2 3 4 →